Fennec Pharmaceuticals Inc. (TSE:FRX - Get Free Report) crossed below its fifty day moving average during trading on Monday . The stock has a fifty day moving average of C$6.89 and traded as low as C$6.40. Fennec Pharmaceuticals shares last traded at C$6.55, with a volume of 1,125 shares traded.
Fennec Pharmaceuticals Stock Performance
The company's 50-day moving average price is C$6.86 and its 200 day moving average price is C$8.84. The stock has a market capitalization of C$180.85 million, a PE ratio of 68.80 and a beta of 0.25. The company has a debt-to-equity ratio of 1,040.68, a quick ratio of 10.17 and a current ratio of 8.02.
Fennec Pharmaceuticals (TSE:FRX - Get Free Report) last issued its quarterly earnings data on Tuesday, August 13th. The biopharmaceutical company reported C($0.27) EPS for the quarter, missing the consensus estimate of C$0.08 by C($0.35). The company had revenue of C$9.94 million during the quarter, compared to analysts' expectations of C$18.67 million. Fennec Pharmaceuticals had a negative return on equity of 1,005.59% and a net margin of 5.59%. On average, equities research analysts expect that Fennec Pharmaceuticals Inc. will post 0.6037736 earnings per share for the current fiscal year.
Fennec Pharmaceuticals Company Profile
(
Get Free Report)
Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.
Further Reading
Before you consider Fennec Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fennec Pharmaceuticals wasn't on the list.
While Fennec Pharmaceuticals currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
